ArticleActa pharmacologica Sinica2022

Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway.

Yi-Kuan Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.